Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Janagliflozin - Sihuan Pharmaceutical Holdings Group

Drug Profile

Janagliflozin - Sihuan Pharmaceutical Holdings Group

Alternative Names: SGLT2 inhibitor - Sihuan

Latest Information Update: 07 Sep 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Sihuan Pharmaceutical Holdings Group
  • Class Antihypercalcaemics
  • Mechanism of Action Sodium-glucose transporter 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Type 2 diabetes mellitus

Most Recent Events

  • 07 Sep 2022 Janagliflozin is still in phase-III trials for Type 2 diabetes mellitus (Combination therapy, Treatment-experienced) in China (PO, Tablet) (NCT03851432)
  • 10 Jun 2019 Safety and efficacy data from clinical trials in healthy volunteers and Type 2 diabetes mellitus released by Sihuan Pharmaceutical
  • 07 Jun 2019 Pharmacokinetics and adverse events data from two single and multiple dose studies in healthy volunteers presented at the 79th Annual Scientific Sessions of the American Diabetes Association (AAD-2019)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top